Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of BPI-3016 in Healthy Subjects
NCT03188848Phase 1Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- May 2017
- Primary completion
- Jul 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing BPI-3016 with Placebo (2 arms). Primary endpoints: Number of subjects with adverse events and serious adverse events at 1 month, Plasma Concentrations of single-dose BPI-3016 at 15 days and 3 more. Status: unknown.
02
Drugs
BPI-3016
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03188848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03188848.